title: Long-term Outcomes After Preoperative Intravitreal Injection of Bevacizumab Before Trabeculectomy for Neovascular Glaucoma.
abstract: OBJECTIVE
  To evaluate the long-term (>3 y) outcomes of patients given preoperative intravitreal bevacizumab (IVB) injection before trabeculectomy for neovascular glaucoma (NVG).
  
  
  METHODS
  We performed a retrospective study of a consecutive series of 12 eyes of 11 patients who underwent trabeculectomy with mitomycin C combined with preoperative IVB for NVG at our institution between April 2009 and April 2010. The mean follow-up period was 43.0±7.0 months (range, 36 to 51 mo), and all patients were followed up for at least 36 months. Surgical success was defined as an intraocular pressure (IOP) of ≤21 mm Hg with or without topical ocular hypotensive medication.
  
  
  RESULTS
  The cumulative surgical success rate was 83.3% at 1 year and 83.3% at 3 years. The mean IOP before surgery was 42.7±9.2 mm Hg, whereas the mean postoperative IOP was significantly lower, being 15.1±3.7 mm Hg at 1 year and 14.2±3.2 mm Hg at 3 years (P<0.01).In contrast, no significant change of the mean visual acuity as compared with the preoperative visual acuity was observed at the follow-up carried out 3 years after the surgery. Intraoperative and early postoperative hyphema was seen in 2 eyes. Recurrence of neovascularization requiring additional IVB injection was seen in 3 eyes.
  
  
  CONCLUSIONS
  Preoperative IVB injection before trabeculectomy for NVG might be effective over the long-term (>3 y) control of the IOP.
authors.affiliation: *Department of Ophthalmology, Yokohama Hodogaya Central Hospital Departments of †Ophthalmology ‡Biostatistics and Epidemiology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Maiko
authors.initials: M
authors.lastname: Inoue
authors.forename: Shin
authors.initials: S
authors.lastname: Yamane
authors.forename: Kentaro
authors.initials: K
authors.lastname: Sakamaki
authors.forename: Akira
authors.initials: A
authors.lastname: Arakawa
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Kadonosono
mesh_terms: D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000008:administration & dosage; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D006988:Hyphema / Q000209:etiology; D007429:Intraocular Pressure / Q000502:physiology; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D011300:Preoperative Care; D012189:Retrospective Studies; D014065:Tonometry, Ocular; D014130:Trabeculectomy; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000477:Alkylating Agents; D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D016685:Mitomycin